~~<i id='F54CF8227E'><strike id='F54CF8227E'><tt id='F54CF8227E'><pre id='F54CF8227E'></pre></tt></strike></i>~~

Home» Wikipedia» Wikipedia

Wikipedia

author：knowledge 2025-09-28 23:16:42 Page View：68

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Chan Zuckerberg Biohub Chicago to focus on inflammation
Next article： Anesthesiologist group: stop taking Ozempic before surgery

focus

Affirmative action in medical school literally saved lives

AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

A Q&A with the global head of Boehringer Ingelheim's innovation unit

MichelPairetCourtesyBoehringerIngelheimLONDON—Ataneventherelastweek,theGermanpharmaceuticalfirmBoehr

Medical records are filled with copy

AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

Stroke deaths set to near 10 million globally by 2050

AdobeThenumberofstrokedeathsworldwideissettoclimb50%tonearly10millionby2050,withmostcasesoccurringin

WSS

Wikipedia

Wikipedia

explore

focus

Stroke deaths set to near 10 million globally by 2050